Cardiovascular
Fund IV exclusively targets company creation and early-stage investing across the UK and the US.
While the biotech sector is optimistic once more, the annual conference did not bring a bounce to many companies.
The $172m acquisition will bring in Kylo-11, a Lp(a) inhibitor with potential once-yearly dosing, as well as other ultra long-acting siRNA candidates directed at APOC3, PCSK9 and other undisclosed targets in cardiovascular diseases.
CEO Vas Narasimhan told attendees at J.P. Morgan that the firm’s considerable financial firepower means it will continue to do “value-creating bolt-ons like you saw last year."
The CEO of Inno Medicine tells Scrip the Chinese company has developed a novel active-targeting nano-liposomal formulation to reverse coronary atherosclerosis plaque, which has yielded positive proof-of-concept Phase Ib/IIa results.
The acquisition signals growing belief in the NLRP3 inhibitor class, where companies are increasingly pursuing cardiometabolic and obesity studies alongside neurodegenerative trials.
Catch up on the developments released in the last days of 2025, from year-end FDA approvals, complete response letters and several trial disappointments.
R&D advances are grist to the pharma mill, and those clinical trials that can be deemed successes are particularly welcome. Here are the top five or so study hits (many come in pairs) that got readers clicking in 2025.
US FDA approval of the cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy marks a milestone for the company after nearly 30 years in business.
The US FDA approved LIB Therapeutics’ Lerochol (lerodalcibep), a PCSK9-inhibiting protein therapeutic injected once-monthly that does not require refrigeration, for adults with high cholesterol, including those with HeFH.
The nasal spray was approved by the US FDA as a rapid acting treatment for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT).
With the help of a purchased priority review voucher, the drug looks likely to become the first aldosterone synthase inhibitor to receive regulatory authorization, ahead of Mineralys' lorundrostat.
Successful stroke data on the oral Factor XIa inhibitor represents the first Phase III success for the class and is a major boost for Bayer’s cardiovascular franchise.
Redemplo is Arrowhead’s first commercial product, and the drug will enter a competitive market. Arrowhead and Ionis have taken different pricing paths, however.
A Phase II trial testing Winrevair in patients with a type of hypertension caused by heart failure met the primary endpoint and could represent a big growth opportunity.
Two Phase III trials of the Factor XIa inhibitor milvexian are ongoing in atrial fibrillation and secondary stroke prevention, but BMS and partner J&J stopped a third in acute coronary syndrome.
CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”
Detailed clinical trial data presented at AHA positions the oral PCSK9 inhibitor on par with injectable drugs on efficacy, but the competitive dynamics remain intense.
Phase III CORE and CORE2 results presented at the AHA meeting in severe hypertriglyceridemia showed durable triglyceride lowering and reductions in acute pancreatitis across patient subgroups, supporting expansion of Tryngolza (olezarsen) into a second, larger indication.
Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.